The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index; none of the 186 sources its claims cite is checked for support yet.
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Open accessAbstract
In the last decade the impressive expansion of our knowledge of the vast microbial community that resides in the human intestine, the gut microbiota, has provided support to the concept that a disturbed intestinal ecology might promote development and maintenance of symptoms in irritable bowel syndrome (IBS). As a correlate, manipulation of gut microbiota represents a new strategy for the treatment of this multifactorial disease. A number of attempts have been made to modulate the gut bacterial composition, following the idea that expansion of bacterial species considered as beneficial (Lactobacilli and Bifidobacteria) associated with the reduction of those considered harmful (Clostridium, Escherichia coli, Salmonella, Shigella and Pseudomonas) should attenuate IBS symptoms. In this conceptual framework, probiotics appear an attractive option in terms of both efficacy and safety, while prebiotics, synbiotics and antibiotics still need confirmation. Fecal transplant is an old treatment translated from the cure of intestinal infective pathologies that has recently gained a new life as therapeutic option for those patients with a disturbed gut ecosystem, but data on IBS are scanty and randomized, placebo-controlled studies are required.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This narrative review argues that disturbed gut microbiota contributes to irritable bowel syndrome (IBS) and that microbiota manipulation is a promising therapeutic strategy. Probiotics have the most supportive evidence, while prebiotics, synbiotics, antibiotics, and fecal microbiota transplantation require further randomized controlled trials.
Key findings
- IBS affects 10%-15% of the general population, and most data support altered luminal and mucosal microbiota in IBS subgroups versus healthy individuals, including decreased Lactobacilli and Bifidobacteria, increased aerobes, and higher mucosal bacteria; a high Firmicutes:Bacteroidetes ratio is found in some IBS patients and appears to correlate with depression and anxiety.
- Probiotics show the strongest evidence: Moayyedi et al examined 18 RCTs including 1650 IBS patients and found probiotics significantly better than placebo for overall symptoms, with significant improvement in pain, flatulence, and bloating but not urgency; Hungin et al selected 19 studies including 1807 patients and reported responder rates of 18%-80% in IBS versus 5%-50% in healthy controls, with a favorable safety profile.
- Didari et al meta-analyzed 15 trials including 882 patients with D-IBS, C-IBS, and A-IBS and found probiotics more effective than placebo in reducing abdominal pain after 8 and 10 wk, with a higher effect at week 8; Table 2 grades evidence as high for global symptom relief and abdominal pain, moderate for bloating/distension, bowel habit, and quality of life, low for constipation and flatus, and very low for diarrhea.
- Rifaximin evidence comes from TARGET 1 and TARGET 2, which included 1260 patients with IBS without constipation: adequate relief of global IBS symptoms was 40.7% vs 31.7% for rifaximin vs placebo, and adequate relief of bloating, abdominal pain, and stool consistency was 40.2% vs 30.2%; FMT data are limited, with Borody et al reporting approximately 50% symptom relief in an early case series and Pinn et al reporting 70% resolution or improvement in refractory IBS patients.
Methods
- Narrative review; no primary data are presented.
- The paper synthesizes human microbiota studies in IBS and therapeutic trials, including meta-analyses and RCTs; for probiotics, it focuses on meta-analyses and extensive reviews published in the last 5 years that screened RCTs in IBS patients.
- Main analysis is qualitative synthesis of microbiota alterations and therapeutic evidence; no formal systematic search strategy or quantitative pooling is described.
Limitations
- The paper states that probiotic trials are highly heterogeneous, often have inadequate sample size, poor study design, and use various probiotic strains; meta-analyses recommend additional RCTs with appropriate endpoints and design.
- It states that prebiotic results are conflicting and may exacerbate IBS symptoms, synbiotic experience is limited with poor-quality studies, FMT data on IBS are scanty and randomized placebo-controlled studies are required, and rifaximin is effective in less than 50% of patients, has been studied mainly in non-constipated IBS, and has unknown long-term and microbiota effects.
- Evident from the text: as a narrative review, it does not report a systematic search, formal risk-of-bias assessment, or quantitative synthesis for most therapeutic sections.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 186 cited sources checked · 0 supported · 0 flagged
In the paper
“Furthermore, a higher degree of temporal instability of the microbiota among IBS patients has been detected.”
What the sources say
- Not checked yetcites [3963]
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Finally mucosal bacteria have also been found to be more abundant in IBS patients than in healthy controls (Table 1).”
What the sources say
- Not checked yetcites [3963]
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Second, it has been reported that approximately 10% of IBS patients refer that their symptoms began following an episode of infectious diarrhea [7577] , the so-called post infectious IBS (PI-IBS), a condition with a clear infective trigger that may alter the normal intestinal microbiota.”
What the sources say
- Not checked yetcites [7577]
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Indeed, probiotic administration was significantly better than placebo at improving overall symptoms.”
What the sources say
- Not checked yetcites [142] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“studies that have examined the effect of probiotics supplementation on fecal SCFAs in humans have provided conflicting results”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“its long-term effects have not been investigated”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“synbiotics lack of sufficient numbers of clinical trials on their efficacy and safeness”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Specific probiotics help relieve overall symptom burden in some patients with IBS High [147,149,150,152,156-157,169, 174,176-178]”
What the sources say
- Not checked yetcites [147] source
- Not checked yetcites [149] source
- Not checked yetcites [150] source
- Not checked yetcites [152] source
- Not checked yetcites [156] source
- Not checked yetcites [157] source
- Not checked yetcites [169] source
- Not checked yetcites [174] source
- Not checked yetcites [176] source
- Not checked yetcites [177] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Probiotics tested to date do not help reduce flatus in patients with IBS Low [147,149-150,156,168,174-175, 178-179,184]”
What the sources say
- Not checked yetcites [147] source
- Not checked yetcites [149] source
- Not checked yetcites [150] source
- Not checked yetcites [156] source
- Not checked yetcites [168] source
- Not checked yetcites [174] source
- Not checked yetcites [175] source
- Not checked yetcites [178] Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-2620. source
- Not checked yetcites [179] source
- Not checked yetcites [184] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Specific probiotics help relieve overall symptom burden in some patients with C-IBS Low [147,156-157]”
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 31
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
In the paper
“Using culture-based techniques and a 16S rRNA gene-based phylogenetic microarray analysis, it has been demonstrated that the diversity of microbial population is reduced, the proportion of specific bacterial groups is altered and the degree of variability in the microbiota composition is different in IBS patients when compared with healthy subjects.”
What the sources say
- Not checked yetcites [3963]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Examples of these modifications are a decreased amount of Lactobacilli and Bifidobacteria along with an increased amount of aerobes relatively to anaerobes in IBS patients.”
What the sources say
- Not checked yetcites [3963]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Probiotics had a favorable safety profile with no difference in adverse events among the 23 specific probiotic treatments and placebo [173] .”
What the sources say
- Not checked yetcites [173] source
Strength:plain· not yet calibratedn = 1,807Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Moreover probiotics showed a statistically significant effect in improving individual symptoms such as pain, flatulence and bloating, but not urgency.”
What the sources say
- Not checked yetcites [142] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“studies demonstrating a strong correlation between the assumption of probiotics and the level of fecal SCFAs in IBS patients are lacking”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“However, few studies have evaluated the efficacy of prebiotics in IBS and existing results are conflicting.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“the effect of rifaximin on gut microbiota composition is essentially unknown”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To date, only anecdotal data have been reported about the efficacy of FMT for IBS treatment, results being far conclusive.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“all metaanalysis point out to the weakness of the majority of the studies and recommend additional RCT trials to confirm the positive findings reported by small studies”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this conceptual framework, probiotics appear an attractive option in terms of both efficacy and safety, while prebiotics, synbiotics and antibiotics still need confirmation.”
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“First, there is increasing evidence of an activation of the intestinal immune system in IBS leading in a micro-inflammation, with studies demonstrating increased concentrations of mucosal intraepithelial lymphocytes [65,66] , mast cells [6669] and 5hydroxytryptaminesecreting enterochromaffin cells [65] .”
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Consistent with this view, the clinical guidance regarding the modulation of intestinal microbiota in IBS provided by the Rome Team Working Group has recently concluded that there is good evidence supporting the concept that the intestinal microbiota is perturbed in patients with IBS [64] .”
What the sources say
- Not checked yetcites [64] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In irritable bowel syndrome (IBS), the altered composition and/or activity of microbiota may induce a disruption of this communication leading to activation of immune system and production of proinflammatory cytokines”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
- Rests on an assumption: Mechanisms by which gut microbiota modulates motility, visceral sensitivity, and neuroimmune signaling in animal models also operate in human IBS.
None of the sources cited for this claim have been checked yet.
In the paper
“Nonetheless gut microbiota modulates gut motor function, which in turn can alter the intestinal microbiota composition.”
What the sources say
- Not checked yetcites [93] Caenepeel P, Janssens J, Vantrappen G, Eyssen H, Coremans G. Interdigestive myoelectric complex in germ-free rats. Dig Dis Sci 1989;34:1180-1184. source
- Not checked yetcites [94] source
- Not checked yetcites [95] Husebye E, Hellström PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci 1994;39:946-956. source
- Not checked yetcites [96] Husebye E, Hellström PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001;280:G368-G380. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, it has been suggested that probiotics might reshape the intestinal ecosystem generating an ecological milieu that is unfavorable for the growth of harmful species by increasing the number of Lactobacilli and Bifidobacteria [199] that will stabilize the intestinal microbiota [174,179] .”
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The clinical benefits of probiotics in IBS are mediated by their effects on gut microbiota composition or function.
In the paper
“as well as an increase in the tissue IL-10/IL-12 ratio ameliorating the quality of life of DIBS [232]”
What the sources say
- Not checked yetcites [232] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Saccharomyces boulardii supplementation induced a significant decrease in blood and tissue levels of proinflammatory cytokines IL8 and TNFa and an increase in antiinflammatory IL-10 levels”
What the sources say
- Not checked yetcites [232] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“the Bifidobacterium lactis Bb12 increased the fecal level of acetate and lactate in preterm infants [243]”
What the sources say
- Not checked yetcites [243] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“leading to en hanced production of SCFAs that are toxic at high concentrations and stimulate 5-HT release from the intestinal nerve endings [239]”
What the sources say
- Not checked yetcites [239] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“but also improved the immune environment of stressed animals and protected against stress induced disturbances in adult gut microflora [246]”
What the sources say
- Not checked yetcites [246] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“bifidobacteriafermented milk increased fecal butyrate, propionate and short-chain fatty acid concentrations but ameliorated symptoms in patients affects by UC [242]”
What the sources say
- Not checked yetcites [242] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Bifidobacterium animalis subsp lactis BB12 ® and Propionibacterium jensenii 702 induced activation of neonatal stress pathways and an imbalance in gut microflora”
What the sources say
- Not checked yetcites [246] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“There are evidence that the gut microbiota modulates the CNS via the ENS, the ANS, the HPA axis and vice versa [124,213]”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An intestinal dysbiosis may lead to alteration of brain-gut axis and probiotics may restore the normal interaction among all components of this pathway.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“long-chain polyunsaturated fatty acids have been tested as active prebiotics [254]”
What the sources say
- Not checked yetcites [254] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The clinical response may be dependent on the prebiotic type and dose, taking into account that low doses may be ineffective and high doses may stimulate colonic gas production.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“lactulose and bran, that are successfully used for constipation, tend to produce substantial amounts of gas and abdominal pain and may aggravate symptoms of IBS [269271]”
What the sources say
- Not checked yetcites [269271]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“GOS lowering flatulence and bloating while also improving the anxiety score [83]”
What the sources say
- Not checked yetcites [83] Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:508-518. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“fructose and sorbitol mixtures produce a modest increase in stool weight, they often increase flatulence and bloating in both healthy volunteers and IBS patients [272,273]”
What the sources say
- Not checked yetcites [272] Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 1990;99:1016-1020. source
- Not checked yetcites [273] Symons P, Jones MP, Kellow JE. Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol. Scand J Gastroenterol 1992;27:940-944. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the limited experience and the poor quality of published studies do not allow any recommendation on their use in IBS”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Few open label trials [64,279] and PCT studies have evaluated the efficacy of synbiotics in both functional pain [280] and IBS, all demonstrating a superiority of the probiotic/prebiotic combinations vs placebo [281283]”
What the sources say
- Not checked yetcites [64] source
- Not checked yetcites [279] Saneian H, Pourmoghaddas Z, Roohafza H, Gholamrezaei A. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 2015;8:56-65.
- Not checked yetcites [280] source
- Not checked yetcites [281283]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“however, these drugs are absorbable causing local and systemic side effects”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“a pooled analysis by Schoenfeld et al [292] has confirmed the safety and tolerability profile of rifaximin in comparison with placebo, with similar incidence of drug-related adverse events”
What the sources say
- Not checked yetcites [292] source
Strength:boosted· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“rifaximin has virtually no systemic absorption, is effective in improving IBS symptoms with low bacterial resistance profile and has a favorable sideeffects profile”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“a large case series of CDI patients has showed rapid response and a cure rate of nearly 90%, without significant adverse event rate [295]”
What the sources say
- Not checked yetcites [295] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“however, the study also included IBD and CDI patients and did not show any distinction within the results between these different diseases”
What the sources say
- Not checked yetcites [305] Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989;150:604. source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“to date, probiotic supplementation and antimicrobial therapy with not absorbable antibiotics are promising treatment”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FMT might be a reasonable option for treating IBS, as it is an inexpensive and easy treatment”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper relies on this without support.
Mechanisms by which gut microbiota modulates motility, visceral sensitivity, and neuroimmune signaling in animal models also operate in human IBS.
“antibiotics-induced intestinal dysbiosis mo dified colonic painrelated and motor responses by upregulation of TLR4 and TLR7 and downregulation of the antinociceptive cannabinoid 1 and mu-opioid receptor in mice [115] .”
The paper relies on this without support.
The clinical benefits of probiotics in IBS are mediated by their effects on gut microbiota composition or function.
“probiotics have been shown effective in modulating several mechanisms that might have a mechanistic role in IBS pathogenesis, including effects on composition of intestinal microbiota”
The paper relies on this without support.
Heterogeneous probiotic trials can be pooled to support a general conclusion that probiotics are efficacious in IBS.
“although a number of metaanalysis or systemic reviews indicate that probiotics may be helpful in the treatment of IBS symptoms, their conclusions vary because of inadequate sample size, poor study design and use of various probiotic strains in the reviewed studies.”
The authors state this as an assumption.
IBS is characterized by impaired intestinal motor functions and by gas retention.
“From almost 4 decades, the assumption that IBS is characterized by impaired intestinal motor functions [205207] and by gas retention [208] has driven the treatment of IBS to small bowel and colonic dys motilities.”
The paper relies on this without support.
Persistence of IBS-like symptoms occurs in a small percentage of patients after a documented episode of intestinal bacterial or viral infection.
“it is widely accepted that persistence of IBS-like symptoms occurs in a small percentage of patients after a documented episode of intestinal bacterial or viral infection”
The paper relies on this without support.
IBS is characterized by increased intestinal permeability, a biomarker of impaired epithelial barrier function.
“animal and epidemiological studies indicate that IBS is characterized by an increased intestinal permeability, a biomarker of impaired epithelial barrier function”
The paper relies on this without support.
Probiotics have a short lifespan within the gut and need repeated doses to keep a constant level.
“An important safety feature of probiotics is that they have a short lifespan within the gut and need repeated doses to keep a constant level.”
The paper relies on this without support.
Alteration in the gut microbiota composition is a relevant pathogenetic factor in IBS.
“The alteration in the gut microbiota composition is increasingly considered to be a relevant pathogenetic factor in IBS, leading to the use of antibiotics as a treatment for this multifactorial syndrome.”
The paper relies on this without support.
Small intestinal bacterial overgrowth may be relevant to at least a subset of IBS patients.
“a SIBO may be relevant to at least a subset of IBS patients, thus justifying an antimicrobial approach”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As previously stated, the long-term PPI use facilitates the induction of enteric infection, and, through secondary changes in microbiota composition, these drugs may influence gut–brain axis functions, prompting IBS onset[117,118].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [117]
In the citing paper
“Patients with IBS with constipation also exhibit a higher proportion of Clostridium, Escherichia coli, Salmonella, Shigella, and Pseudomonas in the gut microbiota [13].”
From Chronic constipation and gut microbiota: current research insights and therapeutic implications (2024) · cites this paper as [13]
Citations
Cites
Items 201–318 of 318
Enck, P., Zimmermann, K., Menke, G., Müller-Lissner, S. A., Martens, U., & Klosterhalfen, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01156.x · Cited by 124
Kerckhoffs, A. P. M., Amor, K. B., Samsom, M., van der Rest, M. E., de Vogel, J., Knol, J., & Akkermans, L. M. A. (2010) · Journal of Medical Microbiology · doi:10.1099/jmm.0.022848-0 · Cited by 124
Tuck, C. J., Muir, J. G., Barrett, J. S., & Gibson, P. R. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.917956 · Cited by 124
Role of fructose-sorbitol malabsorption in the irritable bowel syndrome
Nelis, G. F., Vermeeren, M. A. P., & Jansen, W. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90621-7 · Cited by 123
Perez‐Burgos, A., Wang, L., McVey Neufeld, K., Mao, Y., Ahmadzai, M., Janssen, L. J., Stanisz, A. M., Bienenstock, J., & Kunze, W. A. (2015) · The Journal of Physiology · doi:10.1113/jp270229 · Cited by 123
Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn’s disease
Zhang, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.7213 · Cited by 121
I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life
Lorenzo‐Zúñiga, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8709 · Cited by 120
Kennedy, P. J., Cryan, J. F., Quigley, E. M. M., Dinan, T. G., & Clarke, G. (2014) · Psychological Medicine · doi:10.1017/s003329171400052x · Cited by 120
Aguilera, M., Vergara, P., & Martínez, V. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12154 · Cited by 119
Prebiotic carbohydrates in human milk and formulas
Boehm, G., Stahl, B., Jelinek, J., Knol, J., Miniello, V. L., & Moro, G. E. (2005) · Acta Paediatrica · doi:10.1111/j.1651-2227.2005.tb02149.x · Cited by 119
Applied Principles of Neurogastroenterology: Physiology/Motility Sensation
Kellow, J. E., Azpiroz, F., Delvaux, M. M., Gebhart, G. F., Mertz, H. R., Quigley, E. M. M., & Smout, A. J. P. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.08.061 · Cited by 117
Arslanoğlu, S., Moro, G. E., Boehm, G., Wienz, F., Stahl, B., & Bertino, E. (2012) · PubMed · Cited by 115
Therapeutic faecal microbiota transplantation: current status and future developments
Borody, T. J., Brandt, L. J., & Paramsothy, S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000027 · Cited by 114
Miller, L. E. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i29.4718 · Cited by 114
Bär, F., Von Koschitzky, H., Roblick, U., Bruch, H. P., Schulze, L., Sonnenborn, U., Böttner, M., & Wedel, T. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01258.x · Cited by 113
Lönnermark, E., Friman, V., Lappas, G., Sandberg, T., Berggren, A., & Adlerberth, I. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181b2683f · Cited by 110
TSUCHIYA, J., BARRETO, R., OKURA, R., KAWAKITA, S., FESCE, E., & MAROTTA, F. (2004) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2004.00176.x · Cited by 108
Simrén, M., Svedlund, J., Posserud, I., Björnsson, E. S., & Abrahamsson, H. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00981-x · Cited by 107
Distrutti, E., Cipriani, S., Mencarelli, A., Renga, B., & Fiorucci, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063893 · Cited by 107
Self-citationKiank, C., Taché, Y., & Larauche, M. H. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.08.006 · Cited by 107
Bran supplementation in the treatment of irritable bowel sgndrome
Snook, J. A., & Shepherd, H. A. (1994) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1994.tb00323.x · Cited by 107
Kellow, J., Langeluddecke, P., Eckersley, G., Jones, M. P., & Tennant, C. C. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209011167 · Cited by 106
Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., & Forbes, W. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12735 · Cited by 106
Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-16 · Cited by 103
Abbas, Z., Yakoob, J., Jafri, W., Ahmad, Z., Azam, Z., Usman, M. W., Shamim, S., & Islam, M. (2014) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000094 · Cited by 102
Controlled Trial of Oligofructose in the Management of Irritable Bowel Syndrome
Hunter, J. O., Tuffnell, Q., & Lee, A. J. (1999) · Journal of Nutrition · doi:10.1093/jn/129.7.1451s · Cited by 101
Enck, P., Zimmermann, K., Menke, G., & Klosterhalfen, S. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2008-1027702 · Cited by 100
Barouei, J., Moussavi, M., & Hodgson, D. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046051 · Cited by 99
Dolin, B. J. (2009) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2009.31.10.1441078 · Cited by 99
Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis
Suskind, D. L., Singh, N., Nielson, H., & Wahbeh, G. (2015) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000544 · Cited by 99
Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa
Reshef, L., Kovacs, A., Ofer, A., Yahav, L., Maharshak, N., Keren, N., Konikoff, F. M., Tulchinsky, H., Gophna, U., & Dotan, I. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.041 · Cited by 98
Guyonnet, D., Schlumberger, A., Mhamdi, L., Jakob, S., & Chassany, O. (2009) · British Journal of Nutrition · doi:10.1017/s0007114509990882 · Cited by 95
Pinn, D. M., Aroniadis, O. C., & Brandt, L. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.295 · Cited by 94
Landy, J., Walker, A. W., Li, J. V., Al-Hassi, H. O., Ronde, E., English, N. R., Mann, E. R., Bernardo, D., McLaughlin, S. D., Parkhill, J., et al. (2015) · Scientific Reports · doi:10.1038/srep12955 · Cited by 93
Pinn, D. M., Aroniadis, O. C., & Brandt, L. J. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12479 · Cited by 93
O'Sullivan, E., Barrett, E., Grenham, S., Fitzgerald, P., Stanton, C., Ross, R., Quigley, E., Cryan, J., & Dinan, T. (2011) · Beneficial Microbes · doi:10.3920/bm2011.0015 · Cited by 92
(2007) · PubMed · Cited by 90
Dapoigny, M. C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i17.2067 · Cited by 90
Kalman, D., Schwartz, H. I., Alvarez, P., Feldman, S., Pezzullo, J. C., & Krieger, D. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-85 · Cited by 88
Ambulatory 24-Hour Jejunal Motility in Diarrhea-Predominant Irritable Bowel Syndrome
Schmidt, T., Hackelsberger, N., Widmer, R., Meisel, C., Pfeiffer, A., & Kaess, H. (1996) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529609009131 · Cited by 88
Martín, R., Chain, F., Miquel, S., Natividad, J., Sokol, H., Verdú, E., Langella, P., & Bermúdez-Humarán, L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28549 · Cited by 88
Roberts, L. M., McCahon, D., HOLDER, R. L., Wilson, S., & Hobbs, R. F. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-45 · Cited by 87
Stevenson, C., Blaauw, R., Fredericks, E., Visser, J., & Roux, S. (2014) · Nutrition · doi:10.1016/j.nut.2014.02.010 · Cited by 86
Lyra, A., Krogius-Kurikka, L., Nikkilä, J., Malinen, E., Kajander, K., Kurikka, K., Korpela, R., & Palva, A. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-110 · Cited by 86
Dlugosz, A., Winckler, B., Lundin, E., Zakikhany, K., Sandström, G., Ye, W., Engstrand, L. G., & Lindberg, G. (2015) · Scientific Reports · doi:10.1038/srep08508 · Cited by 85
Daily Stress and Gastrointestinal Symptoms in Women With Irritable Bowel Syndrome
Hertig, V. L., Cain, K. C., Jarrett, M. E., Burr, R. L., & Heitkemper, M. M. (2007) · Nursing Research · doi:10.1097/01.nnr.0000299855.60053.88 · Cited by 84
Søndergaard, B., Olsson, J., Ohlson, K., Svensson, U., Bytzer, P., & Ekesbo, R. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.565066 · Cited by 84
Symptom Provocation in Irritable Bowel Syndrome Effects of Differing Doses of Fructose-Sorbitol
Symons, P., Jones, M. P., & Kellow, J. E. (1992) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529209000167 · Cited by 83
Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome
Theodorou, V., Ait-Belgnaoui, A., Agostini, S., & Eutamene, H. (2014) · Gut Microbes · doi:10.4161/gmic.29796 · Cited by 83
Eskesen, D., Jespersen, L., Michelsen, B., Whorwell, P. J., Müller-Lissner, S., & Morberg, C. M. (2015) · British Journal of Nutrition · doi:10.1017/s0007114515003347 · Cited by 78
Use of broad-spectrum antibiotics and the development of irritable bowel syndrome.
Villarreal, A. A., Aberger, F. J., Benrud, R., & Gundrum, J. D. (2012) · PubMed · Cited by 78
Michail, S. K., & Kenche, H. (2010) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-010-9059-y · Cited by 78
Caldarella, M. P., Milano, A., Laterza, F., Sacco, F., Balatsinou, C., Lapenna, D., Pierdomenico, S. D., Cuccurullo, F., & Neri, M. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40100.x · Cited by 78
The Stable Isotope-based Dynamic Metabolic Profile of Butyrate-induced HT29 Cell Differentiation
Boren, J., Lee, W.-N. P., Bassilian, S., Centelles, J. J., Lim, S., Ahmed, S., Boros, L. G., & Cascante, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302932200 · Cited by 78
Effects of Bifidobacterium infantis 35624 on Post-Inflammatory Visceral Hypersensitivity in the Rat
Johnson, A. C., Greenwood-Van Meerveld, B., & McRorie, J. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1730-y · Cited by 76
Interdigestive myoelectric complex in germ-free rats
Caenepeel, P., Janssens, J., Vantrappen, G., Eyssen, H., & Coremans, G. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01537265 · Cited by 76
Andriulli, A., Neri, M., Loguercio, C., Terreni, N., Merla, A., Cardarella, M. P., Federico, A., Chilovi, F., Milandri, G. L., De Bona, M., et al. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31817fadd6 · Cited by 75
Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome
Hong, K. S., Kang, H. W., Im, J. P., Ji, G. E., Kim, S. G., Jung, H. C., Song, I. S., & Kim, J. S. (2009) · Gut and Liver · doi:10.5009/gnl.2009.3.2.101 · Cited by 75
Gade, J., & Thorn, F. (1989) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813438909103666 · Cited by 72
Multispecies probiotic protects gut barrier function in experimental models
Vivinus-Nébot, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6832 · Cited by 72
Butyrate modulates gene and protein expression in human intestinal endothelial cells
Ogawa, H., Rafiee, P., Fisher, P. J., Johnson, N. A., Otterson, M. F., & Binion, D. G. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.026 · Cited by 70
Rogha, M., Esfahani, M. Z., & Zargarzadeh, A. H. (2014) · Gastroenterology and hepatology from bed to bench. · Cited by 70
Emerging disease model for functional gastrointestinal disorders
Mayer, E. A. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00277-6 · Cited by 69
Childhood Obesity: Immune Response and Nutritional Approaches
Magrone, T., & Jirillo, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00076 · Cited by 67
Quigley, E. M. M. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.009 · Cited by 67
Spaiser, S. J., Culpepper, T., Nieves, C., Ukhanova, M., Mai, V., Percival, S. S., Christman, M. C., & Langkamp-Henken, B. (2015) · Journal of the American College of Nutrition · doi:10.1080/07315724.2014.983249 · Cited by 66
Crosstalk between the immune receptors and gut microbiota
Mu, C., Yang, Y., & Zhu, W. (2015) · Current Protein & Peptide Science · doi:10.2174/1389203716666150630134356 · Cited by 66
Evidence for Pelvic Floor Dyssynergia in Patients With Irritable Bowel Syndrome
Suttor, V. P., Prott, G. M., Hansen, R. D., Kellow, J. E., & Malcolm, A. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181c188e8 · Cited by 66
Is irritable bowel syndrome an inflammatory disorder?
De Giorgio, R., & Barbara, G. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0073-0 · Cited by 64
Metabonomic Understanding of Probiotic Effects in Humans With Irritable Bowel Syndrome
Hong, Y., Hong, K. S., Park, M.-H., Ahn, Y., Lee, J.-H., Huh, C., Lee, J., Kim, I.-K., Hwang, G., & Kim, J. S. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318207f76c · Cited by 63
Bashashati, M., Rezaei, N., Bashashati, H., Shafieyoun, A., Daryani, N. E., Sharkey, K. A., & Storr, M. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01990.x · Cited by 62
Yurrita, L. C., Martín, I. S. M., Ciudad-Cabañas, M. J., Calle-Purón, M. E., & Cabría, M. H. (2014) · PubMed · doi:10.3305/nh.2014.30.2.7565 · Cited by 60
Ojetti, V., Gigante, G. E., Gabrielli, M., Ainora, M. E., Mannocci, A., Lauritano, E. C., Gasbarrini, G. B., & Gasbarrini, A. (2010) · PubMed · Cited by 59
They-intercept of the critical power function as a measure of anaerobic work capacity
Jenkins, D., & Quigley, B. M. (1991) · Ergonomics · doi:10.1080/00140139108967284 · Cited by 58
Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders
Cogliandro, R. F., Antonucci, A., GIORGIO, R. D., Barbara, G., Cremon, C., Cogliandro, L., Frisoni, C., Pezzilli, R., Morselli‐Labate, A. M., Corinaldesi, R., et al. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01783.x · Cited by 57
Bittner, A. C., Croffut, R. M., & Stranahan, M. C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.005 · Cited by 55
Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air?
Hasler, W. L. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.08.038 · Cited by 54
Serra, J., Villòria, A., Azpiroz, F., Lobo, B., Santos, J., Accarino, A. M., & Malagelada, J. R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01447.x · Cited by 54
Rectal Function and Bowel Habit in Irritable Bowel Syndrome
Distrutti, E., Salvioli, B., Azpiroz, F., & Malagelada, J. R. (2004) · The American Journal of Gastroenterology · doi:10.1046/j.1572-0241.2003.04012.x · Cited by 52
Self-citationLudidi, S., Jonkers, D. M. A. E., Koning, C. J., Kruimel, J. W., Mulder, L. H. C., der Vaart, I. B.-V., Conchillo, J. M., & Masclee, A. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12320 · Cited by 51
Quigley, E. M., Donovan, J. P., Lane, M., & Gallagher, T. F. (2005) · Digestive Diseases and Sciences · doi:10.1007/bf01308337 · Cited by 50
The Role of Pathogenic Microbes and Commensal Bacteria in Irritable Bowel Syndrome
Collins, S., Verdu, E., Denou, E., & Bercik, P. (2009) · Digestive Diseases · doi:10.1159/000268126 · Cited by 49
Andrews, P. J., & Borody, T. J. (1993) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb138063.x · Cited by 48
Choi, C. H., Kwon, J. G., Kim, S. K., Myung, S. ‐., Park, K. S., Sohn, C. ‐., Rhee, P. ‐., Lee, K. J., Lee, O. Y., Jung, H. ‐., et al. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12544 · Cited by 46
Armanian, A., Sadeghnia, A., Hoseinzadeh, M., Mirlohi, M., Feizi, A., Salehimehr, N., Saee, N., & Nazari, J. (2014) · Europe PMC (PubMed Central) · Cited by 45
Zar, S., Benson, M. J., & Kumar, D. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200602000-00007 · Cited by 44
Saneian, H., Pourmoghaddas, Z., Roohafza, H., & Gholamrezaei, A. (2015) · Gastroenterology and hepatology from bed to bench. · Cited by 43
Shi, C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i16.4636 · Cited by 43
König, J., & Brummer, R. J. (2014) · Beneficial Microbes · doi:10.3920/bm2013.0033 · Cited by 43
Hydrogen Sulphide Induces μ Opioid Receptor-Dependent Analgesia in a Rodent Model of Visceral Pain
Distrutti, E., Cipriani, S., Renga, B., Mencarelli, A., Migliorati, M., Cianetti, S., & Fiorucci, S. (2010) · Molecular Pain · doi:10.1186/1744-8069-6-36 · Cited by 43
Self-citationHe, Q., Wang, L., Wang, F., & Li, Q. (2014) · Zebrafish · doi:10.1089/zeb.2013.0917 · Cited by 42
Rezaie, A., Nikfar, S., & Abdollahi, M. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.13507 · Cited by 40
Effect of Acute Mucosal Exposure to Lactobacillus rhamnosus GG on Human Colonic Smooth Muscle Cells
Guarino, M. P. L., Altomare, A., Stasi, E., Marignani, M., Severi, C., Alloni, R., Dicuonzo, G., Morelli, L., Coppola, R., & Cicala, M. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31817e1cac · Cited by 40
Schmulson, M. J., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López‐Colombo, A., López‐Vidal, Y., Peláez‐Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A. (2014) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2014.01.001 · Cited by 38
Ammoscato, F., Scirocco, A., Altomare, A., Matarrese, P., Petitta, C., Ascione, B., Caronna, R., Guarino, M. P. L., Marignani, M., Cicala, M., et al. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12232 · Cited by 37
Effects of Growing‐Up Milk Supplemented With Prebiotics and LCPUFAs on Infections in Young Children
Chatchatee, P., Lee, W. S., Carrilho, E., Kosuwon, P., Simakachorn, N., Yavuz, Y., Schouten, B., Graaff, P. L., & Szajewska, H. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000252 · Cited by 37
Peréz-Chanona, E., Mühlbauer, M., & Jobin, C. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.07.014 · Cited by 33
S. Kim, L., Hilli, L., Orlowski, J., Kupperman, J. L., Baral, M., & F. Waters, R. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9297-8 · Cited by 30
Dietary supplementation with fructooligosaccharides attenuates allergic peritonitis in mice
Yasuda, A., Inoue, K., Sanbongi, C., Yanagisawa, R., Ichinose, T., Tanaka, M., Yoshikawa, T., & Takano, H. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.007 · Cited by 29
Dasopoulou, M., Briana, D. D., Boutsikou, Τ., Karakasidou, E., Roma, E. S., Costalos, C., & Malamitsi‐Puchner, A. (2013) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607113510182 · Cited by 29
Schmulson, M., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López-Colombo, A., López Vidal, Y., Peláez-Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A. (2014) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2014.01.004 · Cited by 29
Role of hydrogen sulfide in visceral nociception
Schemann, M., & Grundy, D. (2009) · Gut · doi:10.1136/gut.2008.167858 · Cited by 28
Urbanska, A. M., Paul, A., Bhahena, J., & Prakash, S. (2010) · International Journal of Inflammation · doi:10.4061/2010/894972 · Cited by 28
Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers
Lo Vecchio, A., & Cohen, M. B. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000023 · Cited by 27
Novel immunotherapy approaches to food allergy
Hayen, S. M., Kostadinova, A. I., Garssen, J., Otten, H. G., & Willemsen, L. E. M. (2014) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000109 · Cited by 22
Simrén, M., Svedlund, J., Posserud, I., Fennander, J., Bjornsson, E. S., & Abrahamsson, H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)82562-3 · Cited by 22
Lindfors, P., Törnblom, H., Sadik, R., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.733955 · Cited by 19
MURATA, K., Tomosada, Y., Villena, J., Chiba, E., Shimazu, T., Aso, H., Iwabuchi, N., Xiao, J., Saito, T., & Kitazawa, H. (2014) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.33.1 · Cited by 19
Barouei, J., Moussavi, M., & Hodgson, D. M. (2015) · Beneficial Microbes · doi:10.3920/bm2013.0011 · Cited by 18
Distrutti, E. (2011) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152811794776240 · Cited by 17
Self-citationLong, Z.-R., Yu, C.-H., Yu, Y., Wang, H.-N., & Xiao-xia, C. (2006) · PubMed · Cited by 17
Host–microbe interactions in the small bowel
Davies, J. M., & Abreu, M. T. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000143 · Cited by 16
Staumont, G., Delvaux, M., Fioramonti, J., et al. (1992) · Digestive Diseases and Sciences · doi:10.1007/bf01296502 · Cited by 15
Guarino, M. P. L., Sessa, R., Altomare, A., Cocca, S., Di Pietro, M., Carotti, S., Schiavoni, G., Alloni, R., Emerenziani, S., Morini, S., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.06.001 · Cited by 15
Ansari, R., Sohrabi, S., Ghanaie, O., Amjadi, H., Merat, S., Vahedi, H., & Khatibian, M. (2010) · Indian Journal of Gastroenterology · doi:10.1007/s12664-010-0015-2 · Cited by 15
Mathew, J. (1993) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb138062.x · Cited by 12
Observations on experimentally induced colonic pain.
Ritchie, J. A., Gm, A., & Truelove, S. C. (1972) · PubMed · Cited by 11
Intraduodenal lipids increase perception of rectal distension in IBS patients
Distrutti, E., Susanne, H. K., Stefano, F., Pensi, M., & Morelli, A. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)82630-x · Cited by 10
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- 10.1136/gut.45.2008.ii43 · DOI · Paper page
- 10.1111/j.1365-2982.2009.01447 · DOI
- 10.1111/j.1365-2982.2011.01783 · DOI
- 10.7326/0003-4819-145-8200610170-00004 · DOI
Cited by
Sorted by citations
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
Bifidobacteria and Their Health-Promoting Effects
Hidalgo-Cantabrana, C., Delgado, S., Ruiz, L., Ruas-Madiedo, P., Sánchez, B., & Margolles, A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0010-2016 · Cited by 490
Sex-gender differences in irritable bowel syndrome
Kim, Y. S., & Kim, N. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm18082 · Cited by 322
Gut Microbiota and Iron: The Crucial Actors in Health and Disease
Yilmaz, B., & Li, H. (2018) · Pharmaceuticals · doi:10.3390/ph11040098 · Cited by 317
Slyepchenko, A., Maes, M., Jacka, F. N., Köhler, C. A., Barichello, T., McIntyre, R. S., Berk, M., Grande, I., Foster, J. A., Vieta, E., et al. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448957 · Cited by 278
Metadata
- Authors
- Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Distrutti, Eleonora
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016-02-21
- Volume
- 22
- Issue
- 7
- Pages
- 2219-2241
- ISSN
- 1007-9327 (ISSN-L)
- PMC
- PMC4734998
- OpenAlex
- W2275770700
- Semantic Scholar
- 0efe65174da858617b153324292cf2bd638fa446
- Cited by
- 320
- References
- 318
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 14 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 40 · 2019: 46 · 2018: 35 · 2017: 30 · 2016: 15
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- gut microbiota, irritable bowel syndrome, probiotics, prebiotics, synbiotics, fecal microbiota transplantation, lactobacilli, Bifidobacterium, dysbiosis, antibiotic therapy, treatment options
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Animals, Anti-Bacterial Agents, Bacteria, Humans, Intestines, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Host-Pathogen Interactions, Prebiotics, Synbiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
